RxDoctor Payments Data

Mukul Patil, MD

Urology · Uniontown, PANPI 1033345160

Payments from drug & device makers

$4,590in general payments, 2019–2025

Across 165 payments — averaging $27.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Dendreon Pharmaceuticals LLC$593
  • Astellas Pharma US Inc$580
  • Procept Biorobotics Corporation$441
  • Johnson & Johnson$426
  • Medtronic$340
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,33394%
  • Education$2576%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,590 in reported general payments places this provider in the 65th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$81,490
Medicare patients
359
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron36$26,659
Tamsulosin Hcl606$9,527
GemtesaVibegron15$7,203
Finasteride445$5,874
Silodosin46$4,225
Solifenacin Succinate91$2,899
Estradiol27$2,438
Tolterodine Tartrate ErTolterodine Tartrate12$1,480
Testosterone14$1,248
Terazosin Hcl89$927
Alfuzosin Hcl ErAlfuzosin Hcl51$880
Trospium Chloride23$676
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav88$591
Oxybutynin Chloride ErOxybutynin Chloride62$562
Testosterone Cypionate20$505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$580$26,65936 claims
Sumitomo Pharma America, Inc.Gemtesa$15$7,20315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 596 urology providers in Pennsylvania.

Other urology in Uniontown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →